Business Context and Reporting Period
This Form 8-K reports on the 2022 Annual Meeting of Stockholders held by Nuvation Bio Inc. on May 16, 2022. The meeting addressed governance matters including the election of directors, ratification of the independent auditor, and advisory votes on executive compensation frequency.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
Stockholders representing 94% of Class A and 100% of Class B common stock voted on three proposals:
- Proposal 1 (Election of Directors): All nominees were elected. Kathryn E. Falberg and Oleg Nodelman were elected as Class A directors, and Dr. David Hung was elected as a Class B director.
- Proposal 2 (Ratification of Auditor): Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Proposal 3 (Say-on-Pay Frequency): Stockholders approved, on an advisory basis, a 1-year frequency for soliciting approval of executive compensation.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document is limited to the disclosure of voting outcomes.
Key Facts for Investor Verification
- Verify the tenure of the newly elected directors, who will serve until the 2025 annual meeting.
- Confirm that KPMG LLP is the appointed auditor for the 2022 fiscal year.
- Note that the company will hold annual advisory votes on executive compensation based on the stockholder preference for a 1-year frequency.
- Review the definitive proxy statement filed on April 4, 2022, for detailed biographical information on directors and compensation specifics.